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Dear Dr. Singh,Thank you for your interest to our article.
You are right concerning the possibility of serious adverse
reactions of carbamazepine. Nevertheless, I can’t agree
that avoiding of carbamazepine use in asthma is safer than
its use.
Firstly, decrease of theophylline activity is dangerous
when we have not any other drug which is much more
effective for asthma therapy. In our case carbamazepine is
much more effective for asthma therapy, and therefore it
compensates not only inefficacy of theophylline, but also
many other antiasthma drugs.
Secondly, not only carbamazepine is associated with the
development of severe pulmonary or other disorders. The
same situation is known with almost all other conventional
antiasthma drugs. So, it is well-known that theophylline can
produce seizures.1,2 It is also known that beta-agonists can
provoke severe paradoxical bronchospasm and even sudden
death in patients with asthma.3–7 Moreover, some conven-
tional antiasthmatic drugs also may provoke pulmonary
eosinophilia, like cromolyn,8 beclamethasone,9 or montelu-
kast,10 but no one try to stop their use in therapy of asthma.
Such rare but dangerous adverse reactions are quite
widespread in clinical practice. The question is, what is
more appropriate for patient—to stop the therapy because
of potential adverse reactions, or to manage patients
carefully with the most effective drugs. As we can see,
the severe pulmonary reactions due to carbamazepine are
much more rare in compare to high efficacy of carbamaze-
pine in asthma treatment.
We choose to use the carbamazepine in asthma therapy
under our carefully supervision. None from 63 our patients
had serious pulmonary adverse reaction, but 25 patients
from 33 in carbamazepine group showed full remission of
asthma. I do not think that severe pulmonary reactions are
frequent during use of carbamazepine. We found only few
case reports of carbamazepine pulmonary adverse reaction,
and much more cases of severe adverse effects of beta-
agonists, but it doesn’t hinders the use of beta-agonists in
asthma therapy.
Tens of million of patients used carbamazepine worldwide
during years or even decades since 1960s, and we found only
a few reports concerning pulmonary adverse events due tont matter & 2006 Elsevier Ltd. All rights reserved.
2006.12.008carbamazepine. Taking this into account, we can suppose
that the frequency of such events is very low. Besides,
according WHO data,11 there are more than 1.8 million
patients worldwide with trigeminal neuralgia, and most of
them received carbamazepine for therapy of facial pain. We
can suppose that at least 5% of these patients (90 000) also
have asthma, and we can suppose that at least half of such
patients received carbamazepine due to facial pain. The
total amount of such patients with therapy by carmamaze-
pine should be even more, because the usage of non-
steroidal anti-inflammatory drugs is contraindicated for
therapy of facial pain in these patients due to asthma. In
case of high incidence of pulmonary adverse events due to
carbamazepine we must have at least few published
evidence of this in patients with trigeminal neuralgia and
asthma, but no one exist.
Of course, ‘‘Do not harm’’ is very important, but if we
start to avoid potential harm by terminating of highly
effective drugs, it means that we make much harm due to
avoiding of effective therapy. According this approach, we
must stop vaccination for avoiding of demyelination,12 stop
the use of corticosteroids for avoiding of potential ability of
arterial hypertension,13 avoid to use of adrenergic drugs in
asthma for avoiding of sudden death or paradoxical asthma
exacerbation, etc. The skill of physician is to avoid such
adverse reaction not due to mechanical avoiding of any
therapy, but to avoid them by careful individual manage-
ment of each patient. Otherwise, we must to avoid the
modern pharmacotherapy, which is much more harm for
modern society.
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